AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$FDMT

Kirn David sold $1.1M of FDMT

Kirn David (See Remarks) sold 69,076 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $15.75 ($15.36–$16.42, $1.09M total) across 2 trades on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kirn David
Published Aug 21, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FDMT
Neutral
medium confidence
Mentioned
$FDMT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FDMTNeutralLow
01

Why it matters

Routine insider sale with modest dollar value; unlikely to move the stock significantly.

02

Market read

Provides a fresh primary disclosure of an insider sale; low trading relevance.

03

What to watch

Potential upcoming clinical data releases or financing events not disclosed.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑08‑21 filing

Background

Form 4 filing from SEC EDGAR reporting an insider transaction for 4D Molecular Therapeutics (FDMT).

Company-level read

Ticker impact

$FDMTNeutralMedium confidence
Context

Officer/director Kirn David sold $1.1M of FDMT shares (69,076 shares) via a 10b5-1 plan on 2026-08-19.

Expected impact

Potential slight dip in FDMT price over the next few days.

Evidence & confidence

Sale amount is modest and pre‑arranged; market may view it as routine.

Market effects

Sector

Limited impact on the broader biotech sector; insider sales are common.

Regional

No significant regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be a red flag if insider confidence wanes, suggesting a deeper issue.

Key entities

  • Officer/Director
    Kirn David

    Insider who sold 69,076 FDMT shares.

  • Company
    4D Molecular Therapeutics, Inc.

    Biotech firm whose ticker is FDMT.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FDMT insider trading history →

Related articles

SEP 28
$FDMTMedAI 8/10

4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical…

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The

SEC EDGAR 8-K2 min
AUG 17
$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

rttnews.com7 min
AUG 13
$FDMTMed

4D Molecular Therapeutics, Inc. (FDMT): Results of Operations and Financial Condition

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Prese

SEC EDGAR 8-K6 min